# US 2017/0281659 A1 · Use of thiopyrimidinecarboxamide for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281659 A1
- Document ID: US20170281659A1
- Status: Published application
- Kind: A1
- Application number: 15/627,766
- Filed: 2017-06-20
- Published: 2017-10-05
- Earliest claimed: 2013-08-02
- Assignees: Syntrix Biosystems, Inc.
- Applicants: Syntrix Biosystems Inc.
- Inventors: John A. Zebala; Dean Y. Maeda; Aaron D. Schuler
- Web page: https://patentgrep.com/patent/US20170281659A1

## CPC

- A61K 31/69: Boron compounds
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07F 5/025: {Boronic and borinic acid compounds}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.

## Claims

### Claim 1

A method for treating a CXCR1/2 chemokine mediated disease in a patient in need of such treatment, comprising administering an effective amount of the compound having formula SX-682
or a pharmaceutically acceptable salt or solvate thereof, wherein the patient has atopic dermatitis, asthma, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Alzheimer's disease, atherosclerosis, cerebral ischemia, cardiac ischemia, multiple sclerosis, cystic fibrosis, psoriatic arthritis, tumors dependent on angiogenesis for growth, pancreatitis, alcoholic hepatitis, or alcoholic liver disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein SX-682 or a pharmaceutically acceptable salt or solvate thereof is administered concurrently or sequentially at least one additional agent, drug, medicament, antibody and/or inhibitor useful for the treatment of the CXCR1/2 chemokine mediated disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the additional agent, drug, medicament, antibody and/or inhibitor useful for the treatment of the CXCR1/2 chemokine mediated disease is selected from disease modifying antirheumatic drugs; nonsteroidal antiinflammatory drugs (NSAIDs); COX-2 selective inhibitors; COX-1 inhibitors; immunosuppressives; steroids; biological response modifiers; and other anti-inflammatory agents or therapeutics useful for the treatment of CXCR1/2 chemokine mediated diseases.

### Claim 4 (depends on 2)

The method of claim 2, wherein the additional agent, drug, medicament, antibody and/or inhibitor useful for the treatment of the CXCR1/2 chemokine mediated disease is selected from glucocorticoids, 5-lipoxygenase inhibitors, beta-2 adrenoceptor agonists, muscarinic M1 antagonists, muscarinic M3 antagonists, muscarinic M2 agonists, NK3 antagonists, LTB4 antagonists, cysteinyl leukotriene antagonists, bronchodilators, PDE4 inhibitors, PDE inhibitors, elastase inhibitors, MMP inhibitors, phospholipase A2 inhibitors, phospholipase D inhibitors, histamine H1 antagonists, histamine H3 antagonists, dopamine agonists, adenosine A2 agonists, NK1 and NK2 antagonists, GABA-β agonists, nociceptin agonists, expectorants, mucolytic agents, decongestants, antioxidants, anti-IL-8 antibodies, anti-IL-5 antibodies, anti-IgE antibodies, anti-TNF antibodies, IL-10, adhesion molecule inhibitors, and growth hormones.

### Claim 5 (depends on 2)

The method of claim 2, wherein the additional agent, drug, medicament, antibody and/or inhibitor useful for the treatment of the CXCR1/2 chemokine mediated disease is selected from methotrexate, cyclosporin, leflunimide, sulfasalazine, β-methasone, β-interferon, glatiramer acetate, prednisone, etonercept, and infliximab.

### Claim 6 (depends on 2)

The method of claim 2, wherein the additional agent, drug, medicament, antibody and/or inhibitor useful for the treatment of the CXCR1/2 chemokine mediated disease is selected tenecteplase, TPA, alteplase, abciximab, eftiifbatide), anticoagulants, and heparin.

### Claim 7 (depends on 2)

The method of claim 2, wherein the additional agent, drug, medicament, antibody and/or inhibitor useful for the treatment of the CXCR1/2 chemokine mediated disease is selected from NSAIDs, COX-1 and COX-2 inhibitors, anti-depressants, and anti-convulsants.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-convulsant is selected from gabapentin, carbamazepine, pregabalin, and lamotragine.

### Claim 9

A method for treating a transplant patient in need of such treatment, comprising administering an effective amount of the compound having formula SX-682
or a pharmaceutically acceptable salt or solvate thereof, wherein the patient has graft vs. host reaction, allograft rejections, transplant reperfusion injury, early transplantation rejection, or renal reperfusion injury.

### Claim 10

A method for treating pain in a patient in need of such treatment, comprising administering an effective amount of the compound having formula SX-682
or a pharmaceutically acceptable salt or solvate thereof, wherein the patient has acute inflammatory pain, chronic inflammatory pain, or neuropathic pain.

### Claim 11

A pharmaceutical formulation comprising a therapeutically effective amount of the compound having formula SX-682
or a pharmaceutically acceptable salt or solvate thereof, and a self-emulsifying drug delivery system.

### Claim 12 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the self-emulsifying drug delivery system comprises caprylocaproyl polyoxyl-8 glycerides, steroyl or lauroyl polyoxyl-32-glycerides, or glycerides of C12-C18 fatty acids.

### Claim 13 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is for oral or parenteral administration.

### Claim 14 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is in a unit dosage form, wherein the unit dosage form comprises a unit dose of SX-682.

### Claim 15 (depends on 5)

The pharmaceutical formulation of claim 5, wherein the unit dose is about 0.01 mg to about 1000 mg.

### Claim 16 (depends on 5)

The pharmaceutical formulation of claim 5, wherein the unit dose is about 0.01 mg to about 750 mg.

### Claim 17 (depends on 5)

The pharmaceutical formulation of claim 5, wherein the unit dose is about 0.01 mg to about 500 mg.

### Claim 18 (depends on 5)

The pharmaceutical formulation of claim 5, wherein the unit dose is about 0.01 mg to about 250 mg.

### Claim 19 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation is for transdermal administration.

### Claim 20 (depends on 11)

The pharmaceutical formulation of claim 11, wherein the pharmaceutical formulation is a cream, lotion, aerosol, emulsion, or a transdermal patch.
